diffusion pharmaceuticals
diffusion pharmaceuticals contacts david kalergis chief executive officer diffusion pharmaceuticals inc. (434) 220 - 0718
diffusion pharmaceuticals appoints dr. robert ruffolo to its board of directors - centerwatch news online
diffusion pharmaceuticals inc. ’s iss governance qualityscore as of n / a is n / a .
diffusion pharmaceuticals contacts david kalergis chief executive officer diffusion pharmaceuticals inc. (434) 220 - 0718 dkalergis @ urltoken stephanie carrington icr inc. (646) 277 - 1282 stephanie. carrington @ urltoken
contact: david kalergis, ceo diffusion pharmaceuticals inc. (434) 220 - 0718 dkalergis @ urltoken
diffusion pharmaceuticals contacts david kalergis, chief executive officer diffusion pharmaceuticals inc. (434) 220 - 0718 dkalergis @ urltoken stephanie carrington icr inc. (646) 277 - 1282 stephanie. carrington @ urltoken
diffusion pharmaceuticals soon began to test tsc’s effectiveness in treating glioblastoma, the most common form of brain cancer .
diffusion pharmaceuticals was founded in 2001 by kalergis and john gainer, now an emeritus professor of chemical engineering at uva .
diffusion pharmaceuticals (dffn) has attracted millions of dollars in private investment to develop cancer drugs from a unique molecule invented at the university of virginia .
charlottesville, va, january 8, 2016 (globe newswire) - - diffusion pharmaceuticals llc, a clinical - stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced the successful completion of its merger with restorgenex corporation (otcqx: resx). the combined company is changing its name to diffusion pharmaceuticals inc .
to contact diffusion pharmaceuticals in, please visit urltoken. company data is provided by s & p; global market intelligence. please use this form to report any data issues .
diffusion pharmaceuticals is developing a drug to treat glioblastoma, the most common form of brain cancer. from left: david kalergis, ceo; john gainer, chief scientific officer .
david kalergis chief executive officer diffusion pharmaceuticals inc. (434) 220 - 0718 dkalergis @ urltoken stephanie carrington icr inc. (646) 277 - 1282 stephanie. carrington @ urltoken
diffusion pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard - of - care therapies for life - threatening treatment - resistant solid cancerous tumors, without adding harmful side effects .
diffusion hopes to one day sell its glioblastoma drug to a major pharmaceutical company. kalergis said the chance of a big payout from this sale is not the only thing motivating diffusion’s investors .
kalergis said diffusion’s listing on the nasdaq reassures investors that the company is managing its finances and operations well .
diffusion was approved for listing on the nasdaq last august after completing a merger with restorgenex, an illinois - based company. as the surviving entity in the merger, diffusion retained its board of directors and executive officers .
about diffusion pharmaceuticals diffusion pharmaceuticals is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard - of - care treatments including radiation therapy and chemotherapy. the diffusion technology is a paradigm shift in the approach to the treatment of cancer and other diseases involving hypoxia, or oxygen deprivation, in that it facilitates the diffusion of oxygen to hypoxic tissues. diffusion is developing its lead drug, trans sodium crocetinate (tsc), for use in the many cancer types in which tumor hypoxia is known to diminish the effectiveness of current treatments. tsc targets the cancer’s hypoxic micro - environment, re - oxygenating treatment - resistant tissue and making the cancer cells more vulnerable to the therapeutic effects of treatments such as radiation therapy and chemotherapy, without the apparent addition of any serious side effects .
for accounting purposes, the merger is treated as a
reverse acquisition
under u. s. gaap and diffusion llc is considered the accounting acquirer. accordingly, diffusion llc' s historical results of operations replaced the company' s historical results of operations for all periods prior to the merger. unless otherwise stated, all comparisons in this management' s discussion and analysis to prior year periods are to the results of diffusion pharmaceuticals llc for such period on a stand - alone basis .
diffusion pharmaceuticals inc. , a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia - related diseases, has announced the appointment of robert r. ruffolo, jr. , ph. d. , to its board of directors .
charlottesville, va. , aug. 14, 2017 (globe newswire) - - diffusion pharmaceuticals inc. (nasdaq: dffn) (“diffusion” or “the company”), a clinical - stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia - related diseases, today reported financial results for the three months ended june 30, 2017 and provided a business update .
diffusion is also beginning preparations for clinical trials of tsc in pancreatic cancer patients and as a preliminary treatment for stroke victims .
mts securities, llc. acted as exclusive financial advisor to diffusion and dechert llp acted as legal counsel to diffusion. raymond james & associates, inc. acted as exclusive financial advisor to restorgenex and fox rothschild llp acted as legal counsel for restorgenex .
david kalergis, chairman and chief executive officer of diffusion pharmaceuticals, said, “we are strengthening diffusion’s executive team with the addition of tom as general counsel. tom brings over three decades of biopharmaceutical and legal expertise to our company. he has been instrumental in developing our robust intellectual property strategy. tom will play a critical role in diffusion’s evolution as a publicly traded company and in the strengthening of our ip portfolio as we continue to advance the clinical development of our lead candidate, trans sodium crocetinate (tsc), in oncology indications. ”
diffusion expects to complete a phase 3 trial with more than 200 newly diagnosed glioblastoma patients by 2021, at a cost of about $ 30 million .
the development and diffusion of antibiotics contributed to large improvements in human health and living standards. the antibiotic revolution also spawned the modern pharmaceutical industry. this paper reviews the development of the early antibiotics, and the roles of intellectual property rights (in particular, patents) in their development and diffusion .
charlottesville, va. , march 31, 2017 (globe newswire) - - diffusion pharmaceuticals inc. (nasdaq: dffn), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia - related diseases, today reported financial results for the full year of 2016 and provided an overview of recent operational highlights .
diffusion pharmaceuticals inc. is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard - of - care treatments including radiation therapy and chemotherapy. the diffusion technology is a paradigm shift in the approach to the treatment of cancer and other diseases involving hypoxia, or oxygen deprivation, in that it facilitates the diffusion of oxygen into hypoxic tissue. diffusion is developing its lead drug, trans sodium crocetinate (tsc), for use in the many cancer types in which tumor hypoxia (oxygen deprivation) is known to diminish the effectiveness of current treatments. tsc targets the cancer' s hypoxic micro - environment, re - oxygenating treatment - resistant tissue and making the cancer cells more vulnerable to the therapeutic effects of treatments such as radiation therapy and chemotherapy, without the apparent addition of any serious side effects .
charlottesville, va. , april 01, 2016 (globe newswire) - - diffusion pharmaceuticals inc. (otcqx: dffn), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced that thomas byrne will be transitioning from his current position on the board of directors in order to join the company in a new role as general counsel, effective april 1, 2016. mr. byrne will continue to oversee diffusion’s intellectual property strategy, which he has directed since the company was founded in 2001 .
another charlottesville company, cavion, is developing its own drug to treat brain tumors. the chief executive officers of cavion and diffusion expressed mutual admiration for each other’s accomplishments .
diffusion pharmaceuticals inc. , a clinical - stage biotechnology company, develops therapeutics for the treatment of cancer. its lead product candidate is transcrocetinate sodium, which has initiated phase 3 trials for the treatment of glioblastoma multiforme (gbm); phase 2 clinical trials for the treatment of pancreatic cancer; phase 2 / 3 clinical trials for the treatment of metastatic brain cancer; and phase 2 trial for the treatment of stroke. the company is also developing res - 529, a novel pi3k / akt / mtor pathway inhibitor, which has completed two phase i clinical trials for the treatment of age - related macular degeneration; and is in pre - clinical development stage for the treatment of oncology primarily gbm. diffusion pharmaceuticals inc. was founded in 2001 and is headquartered in charlottesville, virginia .
charlottesville, va. , july 06, 2017 (globe newswire) - - diffusion pharmaceuticals inc. (nasdaq: dffn), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia - related diseases, today announced the appointment of robert r. ruffolo, jr. , ph. d. , to its board of directors, effective immediately .
charlottesville, va. , july 06, 2017 (globe newswire) - - diffusion pharmaceuticals inc. (nasdaq: dffn), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia - related diseases, today announced the appointment of robert r. ruffolo, jr. , ph. d. , to its board of directors, effective immediately .
charlottesville, va. , sept. 29, 2016 (globe newswire) - - diffusion pharmaceuticals inc. (otcqx: dffn), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for the treatment of cancer and various hypoxia - related conditions, today announced the establishment of a new scientific advisory board (“sab”) of distinguished scientists and clinicians. the sab will serve as a resource to diffusion in the continued development of its lead drug candidate, trans sodium crocetinate (tsc), in its many areas of therapeutic use for indications involving hypoxic conditions .
gainer, diffusion’s chief scientific officer, invented trans - sodium crocetinate (tsc), a chemical that re - oxygenates hypoxic tissue without allowing too much oxygen to diffuse into normal tissue .
“becoming a public company is a key element of our strategy, and the completion of this merger is a significant accomplishment for the diffusion team, ” said david kalergis, chairman and chief executive officer of diffusion pharmaceuticals. “we believe that our novel oncology therapeutics for treatment - resistant solid cancers have tremendous potential, and that becoming a publicly traded company affords us the greatest opportunity to capitalize on this large and growing market opportunity. ” mr. kalergis added, “we would like to thank the board and management team of restorgenex for their confidence in merging our two companies for the benefit of our respective stockholders. ”
charlottesville, va. , july 20, 2017 (globe newswire) - - diffusion pharmaceuticals inc. (nasdaq: dffn), a clinical stage biotechnology company developing novel small molecule therapeutics for cancer and other hypoxia - related diseases, today reported the completion of a major production run of its lead drug candidate trans sodium crocetinate (tsc). this drug supply will be used in its planned phase 3 trial which will test tsc in the treatment of newly diagnosed inoperable glioblastoma (gbm) brain cancer patients and is of sufficient quantity to support the entire trial. diffusion plans to initiate this clinical trial by the end of 2017 .
diffusion pharmaceuticals inc. will continue to develop its lead drug candidate, trans sodium crocetinate (tsc), which has demonstrated positive results in a phase 2 clinical trial in patients newly diagnosed with glioblastoma multiforme (gbm). tsc has received orphan drug designation from the u. s. food and drug administration for the treatment of gbm and expects to enter a phase iii study in newly diagnosed gbm patients in 2016. future development of tsc includes other orphan indications. the company is planning to commence a phase ii / iii trial in pancreatic cancer in 2016 with a phase ii / iii study in brain metastases to follow. tsc’s novel mechanism of action enhances the diffusion of oxygen to cancerous tumors, improving the effects of cancer treatments like radiation therapy and chemotherapy. diffusion will review and prioritize products formerly in the restorgenex pipeline .
david kalergis, chairman and chief executive officer of diffusion pharmaceuticals, stated, “during the second quarter we made solid progress in advancing preparations for a planned phase 3 trial of tsc in newly diagnosed inoperable gbm patients, and are on track to complete a protocol review in the third quarter of 2017. assuming fda sign - off on the final protocol design, we plan to begin enrolling patients into the study by the end of 2017. ”
on january 8, 2016, we completed the merger with diffusion llc. as a result of the merger, diffusion llc, the surviving company in the merger, became a wholly - owned subsidiary of the company. immediately following the merger, the former equity holders of diffusion llc owned approximately 84. 1% of the company' s common stock, and the stockholders of restorgenex immediately prior to the merger owned approximately 15. 9% of the company' s common stock, in each case, on a fully - diluted basis and calculated in accordance with the terms of the merger agreement. also in connection with the merger, the pre - merger directors and officers of the company tendered their resignations and the pre - merger directors and officers of diffusion llc were appointed as the new directors and officers of the company. following the completion of the merger, the company changed its corporate name from
restorgenex corporation
to
diffusion pharmaceuticals inc .
and changed the trading symbol of the company' s common stock from
resx
to
dffn .
in november 2016, our common stock was approved for listing on the nasdaq capital market and will continue to trade under the ticker symbol
dffn
.
diffusion pharmaceuticals inc. is a clinical - stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard - of - care (“soc”) treatments including radiation therapy and chemotherapy. diffusion is developing its lead product candidate, trans sodium crocetinate (tsc), for use in the many cancers where tumor hypoxia (oxygen deprivation) is known to diminish the effectiveness of soc treatments. tsc targets the cancer' s hypoxic micro - environment, re - oxygenating treatment - resistant tissue and making the cancer cells more vulnerable to the therapeutic effects of soc treatments without the apparent addition of any serious side effects .
diffusion pharmaceuticals inc. is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard of care treatments including radiation therapy and chemotherapy. diffusion is developing its lead product candidate, trans sodium crocetinate (tsc), for use in the many cancer types in which tumor hypoxia (oxygen deprivation) is known to diminish the effectiveness of current treatments. tsc targets the cancer' s hypoxic micro - environment, re - oxygenating treatment - resistant tissue and making the cancer cells more vulnerable to the therapeutic effects of treatments such as radiation therapy and chemotherapy, without the addition of any serious side effects .
diffusion pharmaceuticals inc. is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard of care treatments including radiation therapy and chemotherapy. diffusion is developing its lead product candidate, trans sodium crocetinate (tsc), for use in the many cancer types in which tumor hypoxia (oxygen deprivation) is known to diminish the effectiveness of current treatments. tsc targets the cancer' s hypoxic micro - environment, re - oxygenating treatment - resistant tissue and making the cancer cells more vulnerable to the therapeutic effects of treatments such as radiation therapy and chemotherapy, without the apparent addition of any serious side effects .
“we are delighted to welcome bob to the board, ” stated david kalergis, chairman and chief executive officer. “his comprehensive pharmaceutical industry experience and drug development knowledge will add real value to diffusion. ”
dr. ruffolo currently serves as president of ruffolo consulting, llc, and sits on the boards of directors for numerous biotechnology companies, in addition to several non - profit charitable organizations. he previously served as president of research and development of wyeth pharmaceuticals and corporate senior vice president of wyeth (now pfizer). previously dr. ruffolo spent 17 years at smithkline beecham pharmaceuticals (now glaxosmithkline) as senior vice president and director of biological sciences, worldwide, and before that, he was chairman of the cardiovascular research committee at lilly research laboratories .
dr. ruffolo currently serves as president of ruffolo consulting, llc, and sits on the boards of directors for numerous biotechnology companies, in addition to several non - profit charitable organizations. he previously served as president of research and development of wyeth pharmaceuticals and corporate senior vice president of wyeth (now pfizer). previously dr. ruffolo spent 17 years at smithkline beecham pharmaceuticals (now glaxosmithkline) as senior vice president and director of biological sciences, worldwide, and before that, he was chairman of the cardiovascular research committee at lilly research laboratories .
david kalergis, chairman and chief executive officer, stated :
the recently received proceeds from our private placement provide diffusion with resources to move forward with our phase 3 clinical program testing of trans sodium crocetinate (tsc) in newly diagnosed gbm patients, as well as advance its use in other indications. diffusion staff, expert consultants and key opinion leaders continue to work together to craft the most cost - effective programs with optimal chances for success .
diffusion pharmaceuticals is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard - of - care treatments including radiation therapy and chemotherapy. diffusion is developing its lead drug, trans sodium crocetinate (tsc), for use in the many cancer types in which tumor hypoxia (oxygen deprivation) is known to diminish the effectiveness of current treatments. tsc targets the cancer’s hypoxic micro - environment, re - oxygenating treatment - resistant tissue and making the cancer cells more vulnerable to the therapeutic effects of treatments such as radiation therapy and chemotherapy, without the apparent addition of any serious side effects. we believe tsc has potential application in other indications involving hypoxia, such as stroke and neurodegenerative diseases .
diffusion pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard - of - care therapies for life - threatening treatment - resistant solid cancerous tumors, without adding harmful side effects. the company is developing its lead drug, trans sodium crocetinate (tsc), which has received orphan drug designation from the fda for use in a number of cancers in which tumor hypoxia (oxygen deprivation) diminishes the efficacy of current treatments. tsc targets the cancer’s hypoxic micro - environment, re - oxygenating treatment - resistant tissue and making the cancerous cells more vulnerable to the therapeutic effects of conventional radiation and chemotherapy .
“we are starting to become a later - stage biotech company, ” said david kalergis, co - founder and ceo of diffusion. “as a phase 3 - ready company, the amount of financing necessary increases very significantly, because the clinical trials are so much bigger. ”
“diffusion has found a high, unmet medical need, ” said cavion ceo andy krouse. “they’ve had some very nice responses in patients. sometimes you have to do a large clinical trial to see if a drug actually works — and they’ve got a nice indication that it should work. ”
the market has been bearish toward diffusion in its first year of trading; the company’s stock price has dropped to under $ 3 per share from a peak of $ 9 soon after its nasdaq debut. hiring accountants and other experts to ensure compliance with federal regulations also imposes significant costs on the company .
“diffusion has reached an important milestone for initiating the phase 3 trial with this successful manufacture of phase 3 - ready tsc, ” said david kalergis, diffusion’s chairman and ceo. “in its end - of - phase - 2 - meeting response, the fda required that any tsc used in upcoming phase 3 studies must be made using commercially - ready processes, both for the active pharmaceutical ingredient (api) and formulated drug product. the necessary advanced production and formulation processes were implemented over the last eighteen months and were cleared with the fda in june, immediately prior to the successful clinical trial supply production run earlier this month. ”
guy m. chisolm, phd, chair of diffusion pharmaceuticals’ sab guy m. chisolm iii, ph. d. was professor in the department of cellular and molecular medicine and vice chair of the lerner research institute at cleveland clinic prior to his recent retirement. he also previously served on cleveland clinic’s board of governors and board of trustees. he also held an appointment as professor of biomedical engineering at case western reserve university. he served on numerous editorial boards and peer review study sections at nih and american heart association. he received a bs from the university of pennsylvania, ms and phd from the university of virginia and postdoctoral research training from the karolinska institute (stockholm) and mit. he has published over 100 articles on vascular cell biology and atherosclerosis .
in january 2016, we completed the merger. for accounting purposes, diffusion llc is considered the acquiring entity in the merger and, as a result, we acquired $ 8. 5 million in cash. in september 2016, we issued convertible notes and received cash proceeds of $ 1. 9 million. as of december 31, 2016, we did not have any existing credit facilities under which we could borrow funds .
david g. kalergis, diffusion’s chairman and chief executive officer, said, “the newly assembled sab is comprised of distinguished leaders in their respective fields, all of whom share the common objective of developing therapeutics to treat hypoxia - induced maladies and address selected unmet medical needs. the sab includes expertise in brain cancer, stroke, peripheral artery disease, and alzheimer’s disease. the composition of this board demonstrates the high level of interest in the significant therapeutic potential of tsc from scientific leaders across a wide array of disciplines. ”
diffusion is now interacting with the fda on details regarding the design and execution of the planned phase 3 study, with initiation planned for later this year. the study will focus on newly diagnosed gbm patients who have been judged by their medical team to be inoperable, usually because of the size or location of the tumor. because of their poor prognosis, these patients are often excluded from participation in other gbm clinical trials. in the company’s phase 2 gbm study, the tsc - treated group showed a nearly four - fold increase in survival at two years, when compared to the historical controls .
during his distinguished career in the pharmaceuticals industry, dr. ruffolo played a significant role in the discovery and / or development of marketed products such as carvedilol for the treatment of heart failure and acute myocardial infarction, ropinirole for parkinson’s disease, dobutamine for congestive heart failure and eprosartan for hypertension. he has authored nearly 500 full - length publications and over 200 abstracts, in addition to editing 15 books. dr. ruffolo was editor - in - chief of four international scientific journals, and has served on the editorial board of 29 international scientific journals. he has received numerous prestigious awards throughout his career, including the discoverers award for carvedilol in heart failure. dr. ruffolo received a b. s. degree in pharmacy and his ph. d. degree in pharmacology from the ohio state university. thereafter, he spent two years as a postdoctoral fellow at the national institutes of health .
to the extent any statements made in this news release deal with information that is not historical, these are forward - looking statements under the private securities litigation reform act of 1995. such statements include, but are not limited to, statements about the company' s plans, objectives, expectations and intentions with respect to future operations and products, the potential of the company' s technology and product candidates, the anticipated timing of future clinical trials and other statements that are not historical in nature, particularly those that utilize terminology such as
would ,
will ,
plans ,
possibility ,
potential ,
future ,
expects ,
anticipates ,
believes ,
intends ,
continue ,
expects ,
other words of similar meaning, derivations of such words and the use of future dates. forward - looking statements by their nature address matters that are, to different degrees, uncertain. uncertainties and risks may cause the company' s actual results to be materially different than those expressed in or implied by such forward - looking statements. particular uncertainties and risks include: general business and economic conditions; the company' s need for and ability to obtain additional financing; and the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance. all forward - looking statements in this news release speak only as of the date of this news release and are based on management' s current beliefs and expectations. diffusion undertakes no obligation to update or revise any forward - looking statement, whether as a result of new information, future events or otherwise .
to the extent any statements made in this news release deal with information that is not historical, these are forward - looking statements under the private securities litigation reform act of 1995. such statements include, but are not limited to, statements about the company' s plans, objectives, expectations and intentions with respect to future operations and products, the potential of the company' s technology and product candidates, the anticipated timing of future clinical trials, the anticipated financial position, operating results and growth prospects of the company and other statements that are not historical in nature, particularly those that utilize terminology such as
would ,
will ,
plans ,
possibility ,
potential ,
future ,
expects ,
anticipates ,
believes ,
intends ,
continue ,
expects ,
other words of similar meaning, derivations of such words and the use of future dates. forward - looking statements by their nature address matters that are, to different degrees, uncertain. uncertainties and risks may cause the company' s actual results to be materially different than those expressed in or implied by such forward - looking statements. particular uncertainties and risks include: general business and economic conditions; the company' s need for and ability to obtain additional financing; and the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance. all forward - looking statements in this news release speak only as of the date of this news release and are based on management' s current beliefs and expectations. diffusion undertakes no obligation to update or revise any forward - looking statement, whether as a result of new information, future events or otherwise .
to the extent any statements made in this news release deal with information that is not historical, these are forward - looking statements under the private securities litigation reform act of 1995. such statements include, but are not limited to, statements about the company' s plans, objectives, expectations and intentions with respect to future operations and products, the potential of the company' s technology and product candidates, the anticipated timing of future clinical trials and protocol review, the anticipated financial position, operating results and growth prospects of the company and other statements that are not historical in nature, particularly those that utilize terminology such as
would ,
will ,
plans ,
possibility ,
potential ,
future ,
expects ,
anticipates ,
believes ,
intends ,
continue ,
expects ,
other words of similar meaning, derivations of such words and the use of future dates. forward - looking statements by their nature address matters that are, to different degrees, uncertain. uncertainties and risks may cause the company' s actual results to be materially different than those expressed in or implied by such forward - looking statements. particular uncertainties and risks include: general business and economic conditions; the company' s need for and ability to obtain additional financing; and the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance. all forward - looking statements in this news release speak only as of the date of this news release and are based on management' s current beliefs and expectations. diffusion undertakes no obligation to update or revise any forward - looking statement, whether as a result of new information, future events or otherwise .
for inquiries related to this message please contact support. for sales inquiries, please visit urltoken
if you believe this to be in error, please confirm below that you are not a robot by clicking
i' m not a robot
below .
please make sure your browser supports javascript and cookies and that you are not blocking them from loading. for more information you can review the terms of service and cookie policy .
the investor relations site (
site
) with which this document is associated is maintained by s & p; global market intelligence (
s & p ;
) on behalf of the organization featured on the site (s & p;' s
client
). these terms and conditions of use (
terms of use
) set forth the terms on which you may use the site, and the information and materials contained therein (the
contents
). by using the site, you agree to these terms of use. if you do not agree to these terms of use, you are not authorized to use the site or contents in any manner, and you should immediately discontinue any use of the site or the contents .
s & p; and / or its client shall have the right at any time to modify or discontinue any aspect of the site or any part of the contents. s & p; may also modify these terms of use without notice. you agree to monitor these terms of use, and to cease all access or use of the site if you no longer agree to abide by the terms of use. your continued use of the site shall constitute acceptance of such modification .
s & p; and the client grant to you a limited, personal license to access the site and to access and download the contents, but only for your own personal, family and household use. you may not use, reproduce, distribute or display any portion of the site for any other purpose, including without limit any commercial purpose. you may use the site and the contents for lawful purposes only. s & p; and client reserve all rights not expressly granted, including the right to terminate your use of the site without notice .
the site contains copyrighted material, trademarks and service marks, and other proprietary information, including but not limited to text, software, and graphics, which materials are owned by s & p; and / or its client. s & p; and client reserve all rights in the contents. you agree not to reproduce, distribute, sell, broadcast, publish, retransmit, disseminate, circulate or commercially exploit the site or the contents without the express written consent of s & p; and the client .
you agree to access the contents and the site manually, by request, and not automatically, through the use of a program, or other means. you agree not to take any action, alone or with others, that would interfere with the operation of the site, to alter the site in any way, or to impede others' access to and freedom to enjoy and use the site as made available by s & p; and s & p; ’s client .
the site and the contents are provided on an
as is
basis. s & p; , its client, and any other providers of the information expressly disclaim all warranties of any kind, express or implied, including without limitation any warranty of accuracy, merchantability, fitness for a particular purpose, or non - infringement .
neither, s & p; , the client nor either of their affiliates, shareholders, officers, employees, agents or representatives shall be liable for any indirect, incidental, exemplary, punitive special or consequential damages arising out of or relating to the site, the use of or inability to use the site, or the contents, even if such party has been advised of the possibility of such damages. in particular, s & p; will not be liable for any loss or damage caused by your reliance on information obtained through the site .
it is your responsibility to evaluate the accuracy, completeness or usefulness of any of the contents available on the site. please seek the advice of professionals regarding the evaluation of any of the information on the site .
the site does not represent an offer or solicitation with respect to the purchase or sale of any security .
these terms of use are the entire agreement between the parties with respect to its subject matter, and it can be amended only via written agreement by s & p. ; these terms and conditions shall be governed by the law of new york, without regard to principals of conflicts or choice of laws .
gene h. barnett, md. , mba, facs dr. gene h. barnett serves as director, rose ella burkhardt brain tumor and neuro - oncology center of the cleveland clinic neurological institute. he has authored more than 210 articles published in leading medical journals and has a particular interest in the areas of neuro - oncology, computer - assisted surgery and stereotactic radiosurgery. dr. barnett created the center for computer - assisted neurosurgery at cleveland clinic, and established cleveland clinic' s innovative neurosurgery program. he holds several patents and continues work on the development of technology in neurosurgery including laser lesioning systems for brain tumors. he graduated summa cum laude from case western reserve university with a b. a. in biology and chemistry, and received his m. d. from case western reserve university school of medicine. he did his residency in neurosurgery and a fellowship in neurology at cleveland clinic, served as an honorary registrar at the university of edinburgh in scotland, and completed a clinical and research fellowship at harvard medical school and massachusetts general hospital. in addition, he completed the executive mba program at the weatherhead school of management of case western reserve university .
connie hess, md, mhs dr. hess is an interventional cardiologist at the university of colorado where she serves as an assistant professor of medicine. she also serves as a clinician scientist for cpc clinical research, a university - affiliated, non - profit cardiovascular and clinical trials research organization. previously, dr. hess was an assistant professor in the department of medicine, division of cardiology at duke university medical center and was a faculty member of the duke clinical research institute (dcri). she received her medical degree from harvard medical school and completed her internship and residency in internal medicine at massachusetts general hospital. dr. hess completed fellowships in cardiology and interventional cardiology at duke university medical center, where she also earned a master of health science degree .
william r. hiatt, md dr. hiatt is an endowed professor for cardiovascular research at the university of colorado school of medicine, division of cardiology with a clinical and research focus in vascular medicine. he is president of cpc clinical research, a university - affiliated, non - profit cardiovascular and clinical trials research organization. research activities include studies evaluating the pathophysiology and epidemiology of peripheral artery disease and related disorders. he received his medical degree cum laude from the university of colorado school of medicine, and was elected to the alpha omega alpha medical society. dr. hiatt completed his residency training at boston university hospital and the university of colorado health sciences center. he was a fellow in internal medicine and vascular medicine at the university of colorado before joining the university of colorado faculty. cpc clinical research currently is running several large cardiovascular outcome trials .
karen c. johnston, md, msc dr. johnston is the harrison distinguished professor and chair of neurology and professor of public health sciences at the university of virginia. dr. johnston’s research has focused on the design and execution of middle phase and phase iii clinical trials. she is currently leading the nih - ninds funded phase iii stroke hyperglycemia insulin network effort (shine) trial in acute ischemic stroke. dr. johnston graduated aoa from the university of rochester school of medicine, where she also did her internal medicine and neurology residency training. she did a vascular neurology fellowship at uva and obtained a master’s degree in outcomes and clinical investigation at uva .
jeffrey l. saver, md, faha, faan, fana dr. saver has been director of the ucla stroke unit since its inception, and professor and sa vice - chair of neurology at the david geffen school of medicine. he is a leader in cerebrovascular research and clinical care. dr. saver has published more than 500 original articles, more than 30 book chapters, and two edited volumes and has been the principal investigator of more than 50 clinical research studies. his research focuses on stroke prevention, acute stroke treatment, stroke diagnosis, and neurocognitive and neurobehavioral consequences of stroke. dr. saver received his medical degree from harvard medical school, and is a graduate of the harvard - longwood neurology training program, the university of iowa fellowship program in behavioral neurology and cognitive neuroscience, and the brown university fellowship program in vascular neurology. dr. saver did his internship at brigham & women' s hospital and his residency at brigham & women' s hospital .
kathleen a. welsh - bohmer, ph. d. , abpp - cn dr. welsh - bohmer is the director of the joseph and kathleen bryan alzheimer’s disease research center (bryan adrc) at duke university medical center, which focuses on basic science discovery and clinical care programs for patients with alzheimer’s disease and other similar memory complaints. under dr. welsh - bohmer’s leadership, the bryan adrc has established broad collaborative ties regionally, nationally and internationally. she also serves as professor, department of psychiatry and behavioral sciences, division of medical psychology and has a joint appointment with the department of neurology at duke university. she holds a bs in psychology from duke university and a phd in psychology from university of virginia. she completed a postdoctoral clinical training fellowship in clinical neuropsychology at university of iowa. she is board certified through the american board of professional psychologists in the practice of clinical neuropsychology .
a phase 2 clinical program, completed in the second quarter of 2015, evaluated 59 patients with newly diagnosed glioblastoma multiforme (gbm). this open label, historically controlled study demonstrated a favorable safety and efficacy profile for tsc combined with standard of care. the u. s. food and drug administration has guided the design of a phase 3 trial in newly diagnosed gbm. additional planned studies, subject to receipt of necessary financing, include a phase 2 trial in pancreatic cancer and a study in brain metastases. due to its novel mechanism of action, tsc has safely re - oxygenated a range of tumor types in our preclinical and clinical studies. the company believes its therapeutic potential is not limited to specific tumors, thereby making it potentially useful to improve standard - of - care treatments of other life - threatening cancers and multiple hypoxia - linked disorders .
with a reader account, it' s easy to send email directly to the contact for this release. sign up today for your free reader account! already have an account? log in here .
globenewswire is one of the world' s largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public .
appointed long - standing pharmaceutical executive robert r. ruffolo, jr. , ph. d. to the company’s board of directors
obtained stockholder approval for a potential offering of up to $ 20. 0 million of series b convertible preferred stock
“we have engaged a premier contract research organization to conduct the phase 3 study and entered into agreements with top - tier partners to manage the mri imaging, clinical data management, drug supply and other functions related to the trial, ” mr. kalergis added. “we completed a major production run of tsc and now have sufficient quantity of the drug to support the entire phase 3 trial. ”
research and development expenses for the second quarter of 2017 were $ 1. 2 million, compared with $ 1. 4 million for the second quarter of 2016. this decrease was attributable to lower expenses related to animal toxicology studies, partially offset by an increase in api and drug manufacturing costs .
general and administrative expenses for the second quarter of 2017 were $ 1. 8 million, compared with $ 2. 3 million for the second quarter of 2016. the decrease was primarily attributable to lower professional fees, partially offset by an increase in salary and salary - related expenses .
the company recorded a loss from operations of $ 3. 0 million for the second quarter of 2017, compared with a loss from operations of $ 3. 8 million for the second quarter of 2016. the narrowed operating loss reflects lower research and development expenses, as well as lower general and administrative expenses .
we recognized a non - cash gain of $ 23. 4 million in the second quarter of 2017 related to the change in fair value of warrant liabilities, which was attributable to a decrease in the fair market value of our common stock during the period. this non - cash gain resulted in net income for the second quarter, which is not indicative of ongoing operations .
net cash used in operating activities for the first half of 2017 was $ 6. 2 million, compared with $ 7. 5 million during the first half of 2016 .
in april 2017 we received the remaining $ 8. 3 million related to our series a financing and as of june 30, 2017, the company had cash and cash equivalents of $ 7. 4 million and a certificate of deposit of $ 10. 0 million .
at our annual meeting of stockholders on june 15, 2017, stockholders approved a potential offering of up to $ 20. 0 million of shares of our series b convertible preferred stock, $ 0. 001 par value per share (“series b preferred stock”), at a price of $ 2. 10 per share, with each share of series b preferred stock being initially convertible into one share of our common stock, subject to adjustment. for each share of series b preferred stock purchased in the offering, the investor will receive a five - year warrant to purchase one share of common stock with an exercise price of $ 2. 31. there is no assurance we will successfully close such an offering at such terms due to the current trading price of our common stock or for any other reason .
this press release is neither an offer to sell, nor a solicitation of an offer to buy, any securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. the series b preferred stock and related warrants described herein have not been and will not be registered under the securities act, or any state securities laws, and unless so registered, may not be offered or sold in the united states except pursuant to an exemption from the registration requirements of the securities act, and applicable state securities laws .
the information and data displayed in this profile are created and managed by s & p; global market intelligence, a division of s & p; global. urltoken does not create or control the content .
only a company representative may request an update for the company profile. documentation will be required .
all data changes require verification from public sources. please include the correct value or values and a source where we can verify .
our data partners will research the update request and update the information on this page if necessary. research and follow - up could take several weeks. if you have questions, you can contact them at bwwebmaster @ businessweek. com .
terms of service trademarks privacy policy ©2018 bloomberg l. p. all rights reserved
html public
- / / w3c / / dtd html 4. 01 transitional / / en
urltoken
nber working paper no. 23257 issued in march 2017 nber program (s): health care, industrial organization
do information differences across u. s. physicians contribute to treatment disparities? this paper uses a unique new dataset to evaluate how changes in physician access to a decision - relevant drug database affect prescribing decisions. our results indicate that doctors using the reference have a significantly greater propensity to prescribe generic drugs, are faster to begin prescribing new generics, and prescribe a more diverse set of products. notably, physicians using the reference database are not faster to prescribe new branded drugs. given that a new generic drug resembles its branded equivalent clinically, these results are consistent with database users responding primarily to the increased accessibility of non - clinical information such as drug price and insurance formulary data; the results also suggest improvements to physician information access have important aggregate implications for the costs and efficiency of medical care. we address possible selection effects in physician types by relying on within - doctor variation and an instrument for adoption timing that is based on the marketing strategy of the drug reference firm .
you may purchase this paper on - line in. pdf format from urltoken ($ 5) for electronic delivery .
you are eligible for a free download if you are a subscriber, a corporate associate of the nber, a journalist, an employee of the u. s. federal government with a
. gov
domain name, or a resident of nearly any developing country or transition economy .
if you usually get free papers at work / university but do not at home, you can either connect to your work vpn or proxy (if any) or elect to have a link to the paper emailed to your work email address below. the email address must be connected to a subscribing college, university, or other subscribing institution. gmail and other free email addresses will not have access .
the nber bulletin on aging and health provides summaries of publications like this. you can sign up to receive the nber bulletin on aging and health by email .
national bureau of economic research, 1050 massachusetts ave. , cambridge, ma 02138; 617 - 868 - 3900; email: info @ urltoken contact us
james poterba is president of the national bureau of economic research. he is also the mitsui professor of economics at m. i. t .
josh mandell | saturday, june 17, 2017 at 7: 30 p. m .
a small charlottesville biopharmaceutical company recently was granted entry to the nasdaq stock exchange .
the company went public in 2016 to fund its first phase 3 clinical trial .
gainer’s initial work on tsc was sponsored by the office of naval research, which was interested in the chemical’s potential to treat severe wounds on the battlefield. gainer eventually obtained a patent for tsc after uva released its patent rights .
gainer, now 78, didn’t expect to still be a pharmaceutical executive more than a decade after retiring from uva. he said the possibility of creating life - saving drugs with his invention drives him to continue working .
“if you have a drug, it’s only useful if it’s out there helping people, ” gainer said .
to pursue the commercialization of tsc, gainer partnered with kalergis, a corporate lawyer and investor who had served on the boards of pharmaceutical research associates (now pra health sciences) and virginia national bank.
diffusion pharmaceuticals inc ( nasdaq : dffn ) is a publicly traded biotechnology and drug development company based in charlottesville , virginia , u.s . it was co-founded in 2001 by american life sciences entrepreneur david kalergis and university of virginia chemical engineering professor john l. gainer . gainer is the inventor of the company ’s platform technology of oxygen diffusion-enhancing compounds and its lead drug , trans sodium crocetinate ( tsc ) . tsc acts to increase the rate at which oxygen moves through blood plasma by the process of diffusion , a phenomenon that forms the basis for the company 's name . tsc and other oxygen diffusion-enhancing compounds , including bipolar trans carotenoid salts ( the subclass to which tsc belongs ) , have been investigated by diffusion pharmaceuticals for treatment of conditions associated with reduced oxygen availability in tissues ( hypoxia ) . 
diffusion pharmaceuticals inc (nasdaq: dffn) is a publicly traded biotechnology and drug development company based in charlottesville, virginia, u.s. it was co-founded in 2001 by american life sciences entrepreneur david kalergis and university of virginia chemical engineering professor john l. gainer. gainer is the inventor of the company ’s platform technology of oxygen diffusion-enhancing compounds and its lead drug, trans sodium crocetinate (tsc). tsc acts to increase the rate at which oxygen moves through blood plasma by the process of diffusion, a phenomenon that forms the basis for the company's name. tsc and other oxygen diffusion-enhancing compounds, including bipolar trans carotenoid salts (the subclass to which tsc belongs), have been investigated by diffusion pharmaceuticals for treatment of conditions associated with reduced oxygen availability in tissues (hypoxia).
diffusion pharmaceuticals inc (nasdaq: dffn) is a publicly traded biotechnology and drug development company based in charlottesville, virginia, u.s. it was co-founded in 2001 by american life sciences entrepreneur david kalergis and university of virginia chemical engineering professor john l. gainer. gainer is the inventor of the company ’s platform technology of oxygen diffusion-enhancing compounds and its lead drug, trans sodium crocetinate (tsc). tsc acts to increase the rate at which oxygen moves through blood plasma by the process of diffusion, a phenomenon that forms the basis for the company's name. tsc and other oxygen diffusion-enhancing compounds, including bipolar trans carotenoid salts (the subclass to which tsc belongs), have been investigated by diffusion pharmaceuticals for treatment of conditions associated with reduced oxygen availability in tissues (hypoxia).